4.3 Article

Decoding molecular mechanism underlying binding of drugs to HIV-1 protease with molecular dynamics simulations and MM-GBSA calculations

Journal

SAR AND QSAR IN ENVIRONMENTAL RESEARCH
Volume 32, Issue 11, Pages 889-915

Publisher

TAYLOR & FRANCIS LTD
DOI: 10.1080/1062936X.2021.1979647

Keywords

HIV-1 protease; binding free energy; molecular mechanism; MM-GBSA; computational alanine scanning

Funding

  1. National Natural Science Foundation of China [12004216]
  2. Shandong Provincial Natural Science Foundation, China [ZR2020QA064]

Ask authors/readers for more resources

The HIV-1 protease (PR) is considered an efficient target for anti-AIDS drug design. Molecular dynamics simulations and post-processing analysis were used to study the binding mechanism of three drugs (LPV, NFV, ATV) to the PR. The results show that the drugs affect the structural flexibility and dynamics behavior of PR, with common interaction clusters, indicating potential targets for clinically available inhibitors.
HIV-1 protease (PR) is thought to be efficient targets of anti-AIDS drug design. Molecular dynamics (MD) simulations and multiple post-processing analysis technologies were applied to decipher molecular mechanism underlying binding of three drugs Lopinavir (LPV), Nelfinavir (NFV) and Atazanavir (ATV) to the PR. Binding free energies calculated by molecular mechanics generalized Born surface area (MM-GBSA) suggest that compensation between binding enthalpy and entropy plays a vital role in binding of drugs to PR. Dynamics analyses show that binding of LPV, NFV and ATV highly affects structural flexibility, motion modes and dynamics behaviour of the PR, especially for two flaps. Computational alanine scanning and interaction network analysis verify that although three drugs have structural difference, they share similar binding modes to the PR and common interaction clusters with the PR. The current findings also confirm that residues located interaction clusters, such as Asp25/Asp25MODIFIER LETTER PRIME, Gly27/Gly27MODIFIER LETTER PRIME, Ala28/Ala28MODIFIER LETTER PRIME, Asp29, Ile47/Ile47MODIFIER LETTER PRIME, Gly49/Gly49MODIFIER LETTER PRIME, Ile50/Ile50MODIFIER LETTER PRIME, Val82/Val82MODIFIER LETTER PRIME and Ile84/Ile84, can be used as efficient targets of clinically available inhibitors towards the PR.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.3
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available